MSH6 and cancer: Promoter methylation was significantly more common in IBD-related dysplasia or cancer in MSH6 (5/10 vs. 1/31, p = 0.002), and TIMP3 (4/9 vs. 1/25, p = 0.012) versus non-IBD related dysplasia or cancer samples